SAB Biotherapeutics (SABS) Short Interest Ratio & Short Volume $2.10 -0.06 (-2.78%) Closing price 09/25/2025 04:00 PM EasternExtended Trading$2.08 -0.02 (-0.95%) As of 09/25/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SAB Biotherapeutics Short Interest DataSAB Biotherapeutics (SABS) has a short interest of 440,500 shares, representing 5.25% of the float (the number of shares available for trading by the public). This marks a -12.25% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.3, indicating that it would take 0.3 days of the average trading volume of 264,712 shares to cover all short positions.Current Short Interest440,500 sharesPrevious Short Interest502,000 sharesChange Vs. Previous Month-12.25%Dollar Volume Sold Short$916.24 thousandShort Interest Ratio0.3 Days to CoverLast Record DateAugust 31, 2025Outstanding Shares10,410,000 sharesFloat Size8,390,000 sharesShort Percent of Float5.25%Today's Trading Volume156,378 sharesAverage Trading Volume264,712 sharesToday's Volume Vs. Average59% Short Selling SAB Biotherapeutics? Sign up to receive the latest short interest report for SAB Biotherapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartSABS Short Interest Over TimeSABS Days to Cover Over TimeSABS Percentage of Float Shorted Over Time SAB Biotherapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 8/31/2025440,500 shares $916.24 thousand -12.3%5.3%0.3 $2.08 8/15/2025502,000 shares $1.11 million -32.7%6.0%0.4 $2.22 7/31/2025745,600 shares $1.40 million +3,433.7%8.9%0.5 $1.88 7/15/202521,100 shares $53.59 thousand -0.9%0.3%0 $2.54 6/30/202521,300 shares $37.38 thousand -37.0%0.3%0.5 $1.76 6/15/202533,800 shares $57.80 thousand -8.2%0.5%0.8 $1.71 5/31/202536,800 shares $68.82 thousand -48.9%0.5%0.8 $1.87 5/15/202572,000 shares $139.68 thousand -27.9%1.0%1.4 $1.94 4/30/202599,900 shares $169.83 thousand +39.7%1.3%1.8 $1.70 4/15/202571,500 shares $98.24 thousand -22.9%1.0%0.7 $1.37 Get the Latest News and Ratings for SABS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 3/31/202592,700 shares $126.07 thousand -19.4%1.2%0.9 $1.36 3/15/2025115,000 shares $185.15 thousand -8.0%1.6%1 $1.61 2/28/2025125,000 shares $213.75 thousand +84.6%1.7%1 $1.71 2/15/202567,700 shares $134.05 thousand -42.8%0.9%0.5 $1.98 1/31/2025118,400 shares $259.30 thousand +121.3%1.6%1 $2.19 1/15/202553,500 shares $186.18 thousand +46.6%0.7%0.7 $3.48 12/31/202436,500 shares $138.34 thousand -35.3%0.5%0.4 $3.79 12/15/202456,400 shares $230.11 thousand -43.0%0.8%0.6 $4.08 11/30/202499,000 shares $289.08 thousand +148.1%1.3%1.1 $2.92 11/15/202439,900 shares $123.69 thousand -32.1%0.5%0.5 $3.10 10/31/202458,800 shares $191.69 thousand -26.3%0.8%0.9 $3.26 10/15/202479,800 shares $193.12 thousand +92.3%1.1%1.6 $2.42 9/30/202441,500 shares $112.05 thousand +37.4%0.6%2.3 $2.70 9/15/202430,200 shares $84.26 thousand -12.7%0.4%1.9 $2.79 8/31/202434,600 shares $101.72 thousand +32.1%0.5%3.7 $2.94 8/15/202426,200 shares $58.95 thousand -8.1%0.4%2.6 $2.25 7/31/202428,500 shares $79.09 thousand +8.0%0.4%1.7 $2.78 7/15/202426,400 shares $76.56 thousand -17.0%0.4%1.6 $2.90 6/30/202431,800 shares $98.58 thousand -7.0%0.4%2 $3.10 6/15/202434,200 shares $107.73 thousand +0.9%0.5%2.1 $3.15 5/31/202433,900 shares $89.50 thousand +50.7%0.5%1.9 $2.64 5/15/202422,500 shares $88.43 thousand No Change0.3%1.2 $3.93 4/30/202422,500 shares $96.53 thousand -12.1%0.3%1.7 $4.29 4/15/202425,600 shares $111.62 thousand -11.4%0.3%1.8 $4.36 3/31/202428,900 shares $131.21 thousand +38.3%0.4%1.7 $4.54 3/15/202420,900 shares $115.37 thousand -15.0%0.3%1.1 $5.52 2/29/202424,600 shares $109.72 thousand -37.1%0.3%1.5 $4.46 2/15/202439,100 shares $217.01 thousand +17.8%0.5%2.9 $5.55 1/31/202433,200 shares $199.20 thousand +90.8%0.4%2.8 $6.00 1/15/202417,400 shares $104.05 thousand -2.8%0.2%1.5 $5.98 12/31/202317,900 shares $12.31 thousand -91.4%N/A2.1 $0.69 12/15/2023207,600 shares $153.29 thousand -11.2%0.3%3 $0.74 11/30/2023233,700 shares $227.16 thousand +1.7%0.7%3.8 $0.97 11/15/2023229,800 shares $209.12 thousand -12.1%0.6%4.4 $0.91 10/31/2023261,400 shares $261.37 thousand -2.2%0.7%5.2 $1.00 10/15/2023267,200 shares $187.57 thousand -2.8%0.7%6.4 $0.70 9/30/2023274,900 shares $173.19 thousand -10.3%0.7%7.4 $0.63 9/15/2023306,500 shares $199.23 thousand -17.5%0.8%8.5 $0.65 8/31/2023371,600 shares $267.55 thousand +8.8%1.0%7 $0.72 8/15/2023341,500 shares $269.79 thousand -12.3%0.9%5.9 $0.79 7/31/2023389,300 shares $315.33 thousand -12.4%1.1%4.7 $0.81 7/15/2023444,400 shares $385.47 thousand -4.1%1.3%1.6 $0.87 6/30/2023463,200 shares $384.46 thousand +27.2%1.3%0.3 $0.83 6/15/2023364,300 shares $329.69 thousand -14.9%1.0%0.3 $0.91 5/31/2023428,100 shares $381.01 thousand -35.7%1.2%0.3 $0.89 5/15/2023665,400 shares $585.55 thousand +28.3%1.9%0.5 $0.88 4/30/2023518,600 shares $465.86 thousand +287.6%1.5%0.4 $0.90 4/15/2023133,800 shares $97.07 thousand -3.2%0.4%0.1 $0.73 3/31/2023138,200 shares $60.81 thousand -30.1%0.4%3.4 $0.44 3/15/2023197,800 shares $100.88 thousand +17.5%0.6%4.3 $0.51 2/28/2023168,300 shares $109.40 thousand +14.1%0.5%3.2 $0.65 2/15/2023147,500 shares $97.79 thousand -2.8%0.5%2.7 $0.66 1/31/2023151,700 shares $103.06 thousand +3.1%0.5%2.3 $0.68 1/15/2023147,100 shares $109.43 thousand -14.4%0.5%2.1 $0.74 12/30/2022171,800 shares $101.34 thousand -14.4%0.6%2.5 $0.59 12/15/2022200,700 shares $184.68 thousand -6.1%0.7%2.8 $0.92 11/30/2022213,700 shares $230.80 thousand -11.1%0.8%2.8 $1.08 11/15/2022240,300 shares $254.72 thousand +8.2%0.9%3.1 $1.06 10/31/2022222,200 shares $199.98 thousand -15.3%0.8%3.1 $0.90 10/15/2022262,400 shares $208.63 thousand +7.7%0.9%3.8 $0.80 9/30/2022243,600 shares $170.76 thousand +22.8%0.9%3.6 $0.70 9/15/2022198,300 shares $164.59 thousand -22.1%0.7%3.6 $0.83 8/31/2022254,600 shares $178.25 thousand +6.3%1.0%4.5 $0.70 8/15/2022239,500 shares $287.40 thousand -6.4%0.9%4.9 $1.20 7/31/2022255,900 shares $276.37 thousand -3.4%1.0%5.3 $1.08 7/15/2022265,000 shares $315.35 thousand -8.8%1.0%5.7 $1.19 6/30/2022290,700 shares $421.52 thousand +17.1%1.1%4.5 $1.45 6/15/2022248,300 shares $330.24 thousand -19.8%1.0%1.2 $1.33 5/31/2022309,600 shares $606.82 thousand +19.8%1.2%1.5 $1.96 5/15/2022258,500 shares $514.42 thousand -2.5%1.1%1.1 $1.99 4/30/2022265,100 shares $662.75 thousand +3.7%1.1%1.2 $2.50 4/15/2022255,700 shares $736.42 thousand -12.8%1.0%1.1 $2.88 3/31/2022293,200 shares $1.10 million -6.7%1.2%1.3 $3.76 3/15/2022314,400 shares $572.21 thousand -30.0%1.3%2.9 $1.82 2/28/2022449,000 shares $2.23 million -5.9%1.8%2.7 $4.96 2/15/2022477,000 shares $2.57 million -0.1%1.9%2.3 $5.39 1/31/2022477,400 shares $2.77 million +19.7%1.9%1.9 $5.81 1/15/2022398,700 shares $2.69 million -26.9%1.6%1 $6.75 12/31/2021545,400 shares $4.26 million No Change2.2%0.8 $7.81 SABS Short Interest - Frequently Asked Questions What is SAB Biotherapeutics' current short interest? Short interest is the volume of SAB Biotherapeutics shares that have been sold short but have not yet been closed out or covered. As of August 31st, traders have sold 440,500 shares of SABS short. 5.25% of SAB Biotherapeutics' shares are currently sold short. Learn More on SAB Biotherapeutics' current short interest. What is a good short interest percentage for SAB Biotherapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.25% of SAB Biotherapeutics' floating shares are currently sold short. Is SAB Biotherapeutics' short interest increasing or decreasing? SAB Biotherapeutics saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 440,500 shares, a decline of 12.3% from the previous total of 502,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is SAB Biotherapeutics' float size? SAB Biotherapeutics currently has issued a total of 10,410,000 shares. Some of SAB Biotherapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. SAB Biotherapeutics currently has a public float of 8,390,000 shares. How does SAB Biotherapeutics' short interest compare to its competitors? 5.25% of SAB Biotherapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to SAB Biotherapeutics: Curis, Inc. (1.40%), Bolt Biotherapeutics, Inc. (5.86%), Amgen Inc. (2.20%), Gilead Sciences, Inc. (1.42%), Vertex Pharmaceuticals Incorporated (1.42%), Regeneron Pharmaceuticals, Inc. (2.77%), Alnylam Pharmaceuticals, Inc. (3.07%), Biogen Inc. (3.23%), United Therapeutics Corporation (6.17%), Incyte Corporation (3.89%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($73.23 billion), Invesco QQQ ($29.52 billion), iShares Russell 2000 ETF ($20.82 billion), iShares 20+ Year Treasury Bond ETF ($10.76 billion), Palo Alto Networks, Inc. ($9.37 billion), Strategy Inc ($7.58 billion), Invesco S&P 500 Equal Weight ETF ($6.78 billion), SPDR S&P Biotech ETF ($6.72 billion), AppLovin Corporation ($6.37 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($6.29 billion). View all of the most shorted stocks. What does it mean to sell short SAB Biotherapeutics stock? Short selling SABS is an investing strategy that aims to generate trading profit from SAB Biotherapeutics as its price is falling. SABS shares are trading down $0.06 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against SAB Biotherapeutics? A short squeeze for SAB Biotherapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of SABS, which in turn drives the price of the stock up even further. How often is SAB Biotherapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SABS, twice per month. The most recent reporting period available is August, 31 2025. More Short Interest Resources from MarketBeat Related Companies Curis Short Interest Data Bolt Biotherapeutics Short Interest Data Amgen Short Interest Data Gilead Sciences Short Interest Data Vertex Pharmaceuticals Short Interest Data Regeneron Pharmaceuticals Short Interest Data Alnylam Pharmaceuticals Short Interest Data Biogen Short Interest Data United Therapeutics Short Interest Data Incyte Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:SABS) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredChina Targets MAGA In Stealth Trade War TacticsChina is deliberately targeting the economic backbone of conservative America - The very industries that supp...Goldco Precious Metals | SponsoredCollege grad makes $64,000 a monthNothing hurts like a missed opportunity... And with AI stocks like Nvidia, Palantir, and Oracle continuing...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SABS Stock Alerts